Proteinuria, the presence of excess protein in urine, is more than just an abnormal lab result. It can signal kidney damage, heart disease risk, or temporary health changes. Understanding how to manage and reduce protein in the urine is essential for protecting kidney function and overall health.

Understanding Treatment Goals in Proteinuria

When protein appears in your urine, treatment focuses on several important goals. The main aim is to protect your kidneys from further damage and slow down any disease progression. Healthcare professionals work to reduce the amount of protein leaking into the urine, which can help preserve kidney function over time. Treatment also addresses underlying conditions that may be causing the protein leak, such as diabetes or high blood pressure. Additionally, managing proteinuria helps reduce the risk of cardiovascular disease, since protein in the urine often signals increased risk for heart problems.

The approach to treating proteinuria depends heavily on what is causing it and how severe it is. Some cases resolve on their own, especially when caused by temporary conditions like dehydration, fever, or intense exercise. Other cases require ongoing medical management because they stem from chronic kidney disease or other long-term health conditions. The stage of kidney disease, the amount of protein in the urine, and the presence of other health problems all influence the treatment plan.

Standard treatments approved by medical societies exist for proteinuria, particularly when it is linked to kidney disease. At the same time, researchers continue to explore new therapies through clinical trials. These investigational treatments aim to find better ways to reduce protein in the urine and protect kidney function. The goal is not just to improve laboratory numbers but to enhance quality of life, prevent complications, and help people maintain their health for as long as possible.

Standard Medical Treatment for Proteinuria

The foundation of treating proteinuria lies in using medications that target the renin-angiotensin-aldosterone system, which is a complex network of hormones and enzymes that regulate blood pressure and fluid balance in the body. Two main classes of drugs are used for this purpose: ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin receptor blockers, also called sartans). These medications work by reducing pressure inside the tiny filtering units of the kidneys called glomeruli, which helps prevent protein from leaking into the urine.^[10]

ACE inhibitors block an enzyme that produces angiotensin II, a substance that causes blood vessels to narrow. By preventing this narrowing, especially in the blood vessels leaving the kidney filters, ACE inhibitors reduce the pressure that pushes protein through the kidney’s filtering system. Studies have shown that these medications can reduce proteinuria significantly and may slow the progression of kidney disease by up to fifty percent in patients with protein in their urine.^[10][15]

ARBs work through a slightly different mechanism but achieve similar results. Instead of blocking the enzyme that makes angiotensin II, ARBs block the places where angiotensin II attaches to blood vessels. This prevents the blood vessels from narrowing in response to this hormone. Both ACE inhibitors and ARBs are effective at reducing proteinuria in people with and without diabetes. Clinical guidelines recommend using one or the other, but not both together, as combining them increases the risk of side effects without providing additional benefits.^[10][15]

Blood pressure control is absolutely critical in managing proteinuria. Most guidelines recommend keeping blood pressure below 130/80 mm Hg for individuals with kidney disease and proteinuria. Various blood pressure medications may be used in addition to ACE inhibitors or ARBs. These include diuretics, which help the body remove excess fluid and salt, and calcium channel blockers, which relax blood vessels. Diuretics are particularly helpful when proteinuria causes swelling in the face, hands, feet, or ankles.^[10][11]

For people with diabetes, managing blood sugar levels is an essential part of treating proteinuria. Medications called SGLT2 inhibitors have shown promise in reducing protein in the urine while also protecting the kidneys. These drugs help the kidneys remove excess glucose through the urine. Keeping blood sugar at normal or near-normal levels helps prevent further kidney damage and may reduce the amount of protein leaking into the urine.^[11]

Diet modifications play an important supporting role in standard treatment. Reducing salt intake to less than 2,300 milligrams per day helps control blood pressure and reduces fluid retention. Limiting dietary protein may also be recommended, as consuming too much protein can strain the kidneys and increase protein leakage into the urine. The appropriate amount of protein depends on the stage of kidney disease, and consulting with a dietitian can help determine the right balance. Plant-based protein sources appear to be easier on the kidneys compared to animal proteins.^[11][14]

Treatment duration varies depending on the underlying cause. For temporary proteinuria, no specific treatment is needed beyond addressing the trigger, such as rehydrating after exercise or recovering from a fever. For chronic proteinuria related to kidney disease, treatment is typically lifelong. Regular monitoring through urine tests helps healthcare providers assess whether the treatment is working and make adjustments as needed.^[10]

Side effects from proteinuria medications can occur. ACE inhibitors may cause a persistent dry cough in some people, which is usually harmless but can be bothersome. Both ACE inhibitors and ARBs can cause high potassium levels in the blood, which requires monitoring through blood tests. Some people may experience dizziness, especially when standing up quickly, as these medications lower blood pressure. Kidney function may temporarily worsen when starting these medications, but this usually improves over time. Rarely, more serious side effects such as swelling of the face or throat can occur and require immediate medical attention.^[10]

Innovative Approaches in Clinical Trials

Researchers are actively testing new treatments for proteinuria in clinical trials around the world. These studies explore different ways to reduce protein leakage and protect kidney function beyond what standard treatments can achieve. While some of these therapies are still in early testing phases, others are advancing toward potential approval for widespread use.

One area of intense investigation involves medications that target the complement system, which is part of the body’s immune response. In certain kidney diseases like IgA nephropathy and complement 3 glomerulopathy, an overactive complement system contributes to kidney inflammation and proteinuria. Researchers are testing drugs that block specific components of the complement system to reduce this inflammation. These medications work by preventing immune proteins from attacking the kidney filters. Early studies have shown that some complement inhibitors can reduce proteinuria and slow kidney function decline in specific patient populations.

Newer medications in the SGLT2 inhibitor class are being studied not just for diabetes but specifically for their kidney-protective effects in people with proteinuria. Clinical trials are evaluating whether these drugs can reduce proteinuria and slow chronic kidney disease progression even in people without diabetes. The trials involve patients with various levels of kidney function and different amounts of protein in their urine. Some studies have reported encouraging results, showing reductions in proteinuria and better preservation of kidney function compared to standard treatment alone.

Researchers are also investigating medications that work on a cellular level to protect the kidney’s filtering structures. Some experimental drugs target molecules called endothelin receptors, which affect how blood flows through the kidneys. By blocking these receptors, these medications may reduce pressure in the kidney filters and decrease protein leakage. Clinical trials are currently testing whether combining these endothelin receptor blockers with standard ACE inhibitors or ARBs provides additional benefits in reducing proteinuria.

Another promising avenue involves drugs that target inflammation pathways in the kidneys. Some clinical trials are testing medications that block specific inflammatory molecules called cytokines. These drugs aim to reduce the inflammation that damages kidney filters and causes protein to leak into the urine. While still in early phases of testing, some of these anti-inflammatory approaches have shown potential in reducing proteinuria in patients whose condition has not responded well to standard treatments.

For certain causes of proteinuria, such as focal segmental glomerulosclerosis (FSGS), researchers are exploring treatments that target the structure of the kidney filters themselves. One approach involves using medications that strengthen the connections between cells in the glomeruli, potentially making them less likely to allow protein to pass through. These therapies are in various phases of clinical trials, with some showing encouraging results in reducing proteinuria and improving kidney function markers.

Gene therapy approaches are also being investigated for inherited forms of kidney disease that cause proteinuria. These experimental treatments aim to correct genetic defects that lead to abnormal kidney function. While still in very early research phases, gene therapy holds promise for conditions like Alport syndrome and certain forms of polycystic kidney disease, where genetic mutations directly cause proteinuria and kidney damage.

Clinical trials for proteinuria treatments typically progress through three main phases. Phase I trials focus primarily on safety, testing the new treatment in a small group of volunteers or patients to understand how the body processes the drug and what side effects might occur. Phase II trials expand to include more participants and begin evaluating whether the treatment is effective at reducing proteinuria while continuing to monitor safety. Phase III trials are large studies that compare the new treatment to standard care, involving hundreds or even thousands of patients across multiple medical centers. These trials provide the evidence needed to determine whether a new treatment should be approved for general use.

Eligibility for proteinuria clinical trials varies depending on the specific study. Generally, trials look for participants with persistent proteinuria confirmed through multiple urine tests. Many trials specify a minimum level of protein in the urine for enrollment. Some studies focus on specific causes of proteinuria, such as diabetic kidney disease or IgA nephropathy, while others accept participants with various underlying conditions. Most trials have requirements about kidney function level, measured by estimated glomerular filtration rate (eGFR), and may exclude people with very advanced kidney disease or those already on dialysis.

Clinical trials are being conducted in many locations worldwide, including major medical centers in the United States, Europe, and Asia. Some studies specifically focus on populations at higher risk for kidney disease, such as people with diabetes or high blood pressure. Poland and other European countries participate in multinational trials testing new proteinuria treatments. Interested patients can search for available trials through healthcare provider recommendations or online clinical trial registries.

Most common treatment methods

• Medications targeting the renin-angiotensin-aldosterone system
  • ACE inhibitors that block angiotensin-converting enzyme to reduce pressure in kidney filters and decrease protein leakage
  • Angiotensin receptor blockers (ARBs) that prevent blood vessels from narrowing in response to angiotensin II
  • Both classes shown to reduce proteinuria by up to fifty percent and slow kidney disease progression
  • Typically used as single therapy rather than in combination to avoid side effects
• Blood pressure management
  • Target blood pressure below 130/80 mm Hg for people with kidney disease
  • Diuretics to remove excess fluid and salt from the body
  • Calcium channel blockers to relax blood vessels
  • Multiple medications often needed to achieve blood pressure goals
• Diabetes management for diabetic kidney disease
  • Blood sugar control to normal or near-normal levels
  • SGLT2 inhibitors that help kidneys remove excess glucose while protecting kidney function
  • Regular monitoring of blood glucose levels
  • Diet modifications to distribute carbohydrates throughout meals
• Dietary modifications
  • Low-sodium diet with less than 2,300 milligrams of salt per day
  • Controlled protein intake based on kidney function stage
  • Preference for plant-based protein sources over animal proteins
  • Working with a registered dietitian for personalized meal planning
• Lifestyle changes
  • Regular physical activity and exercise appropriate for health status
  • Weight management to reduce strain on kidneys
  • Smoking cessation to protect kidney function
  • Adequate hydration for temporary proteinuria caused by dehydration

Managing Specific Causes of Proteinuria

When proteinuria results from specific kidney diseases, treatment must address the underlying condition. For glomerulonephritis, which involves inflammation of the kidney filters, treatment may include corticosteroids or immunosuppressive medications to reduce inflammation. The specific approach depends on the type of glomerulonephritis and its severity. Some forms respond well to medication, while others may be more resistant to treatment.

Lupus nephritis, which occurs when the autoimmune disease lupus affects the kidneys, often requires aggressive treatment with immunosuppressive drugs. These medications work to calm down the overactive immune system that is attacking the kidneys. Treatment typically involves a combination approach with corticosteroids and other immunosuppressive agents. The goal is to achieve remission, meaning the inflammation stops and proteinuria decreases significantly.

For diabetic kidney disease, the most common cause of proteinuria, treatment focuses on controlling blood sugar and blood pressure. Studies have shown that keeping hemoglobin A1c below seven percent can help prevent worsening of proteinuria. Newer diabetes medications, particularly SGLT2 inhibitors and GLP-1 receptor agonists, have shown kidney-protective effects beyond their blood sugar-lowering properties. These medications may reduce proteinuria and slow the decline in kidney function over time.

When high blood pressure is the primary cause of proteinuria, aggressive blood pressure control becomes the cornerstone of treatment. Multiple blood pressure medications are often needed to reach target levels. Regular monitoring helps ensure blood pressure stays well controlled, as even temporary elevations can worsen proteinuria and accelerate kidney damage.

Monitoring and Follow-up Care

Regular monitoring is essential for anyone with proteinuria. Healthcare providers typically check urine protein levels every few months to see if treatment is working. The goal is often to achieve at least a fifty percent reduction in proteinuria, as this level of improvement has been associated with better long-term kidney outcomes. Some patients may achieve complete resolution of proteinuria, while others may have persistent protein in their urine despite treatment.

Blood tests to check kidney function are also performed regularly. These tests measure creatinine and calculate the estimated glomerular filtration rate (eGFR), which indicates how well the kidneys are filtering blood. Monitoring trends in these values over time helps healthcare providers assess whether kidney disease is stable, improving, or progressing. Blood tests also check for potential side effects from medications, such as high potassium levels or changes in blood cell counts.

Blood pressure monitoring, both at home and during medical visits, provides important information about treatment effectiveness. Keeping a blood pressure log helps healthcare providers make accurate adjustments to medications. Many people with proteinuria benefit from monitoring their blood pressure at home daily or several times per week, which provides more complete information than occasional clinic measurements.

Lifestyle factors require ongoing attention. Weight management, dietary compliance, physical activity levels, and smoking status all influence proteinuria and kidney health. Healthcare teams often include dietitians, diabetes educators, and other specialists who provide support for maintaining healthy habits over the long term. These lifestyle modifications work together with medications to provide the best possible outcomes.